Doxorubicin cardiotoxicity and target cells: a broader perspective

被引：56

作者：

De Angelis A. ^{[1
]}

Urbanek K. ^{[1
]}

Cappetta D. ^{[1
]}

Piegari E. ^{[1
]}

Ciuffreda L.P. ^{[1
]}

Rivellino A. ^{[1
]}

Russo R. ^{[1
]}

Esposito G. ^{[1
]}

Rossi F. ^{[1
]}

Berrino L. ^{[1
]}

机构：

[1] Department of Experimental Medicine, Section of Pharmacology, Second University of Naples, via Costantinopoli 16, Naples

来源：

Cardio-Oncology | / 2卷 / 1期

关键词：

Doxorubicin cardiotoxicity; Myocardial homeostasis; Progenitor cells;

D O I：

10.1186/s40959-016-0012-4

中图分类号：

学科分类号：

摘要：

The cardiotoxicity of doxorubicin is becoming an interdisciplinary point of interest given a growing population of cancer survivors. The complex and not completely understood pathogenesis of this complication makes difficult to design successful preventive or curative measures. Although cardiomyocyte has been considered a classical cellular target, other cells including various types of undifferentiated cells are involved in myocardial homeostasis. Such perspective may shed light on previously unrecognized aspects of cardiotoxicity and promote new experimental and clinical cardioprotective strategies. In this review, different cellular targets of doxorubicin are discussed with the focus on cardiac progenitor cells, oxidative stress, DNA damage, senescence and apoptosis all of which contribute to their compromised functional properties. © 2016, De Angelis et al.

引用

共 109 条

[1]

Grein A., Spalla C., Di Marco A., Canevazzi G., Descrizione e classificazione di un attinomicete (streptomyces peucetius sp. nova) produttore di una sostanza ad attivita antitumorale-La Daunomicina, Giorn Microbiol, 11, pp. 109-118, (1963)

[2]

Bonadonna G., Monfardini S., De Lena M., Fossati-Bellani F., Clinical evaluation of adriamycin, a new antitumour antibiotic, Br Med J, 3, pp. 503-506, (1969)

[3]

Praga C., Beretta G., Vigo P.L., Lenaz G.R., Pollini C., Bonadonna G., Et al., Adriamycin cardiotoxicity: a survey of 1273 patients, Cancer Treat Rep, 63, pp. 827-834, (1979)

[4]

Herman E.H., Ferrans V.J., Jordan W., Ardalan B., Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits, Res Commun Chem Pathol Pharmacol, 31, pp. 85-97, (1981)

[5]

Herman E.H., el-Hage A.N., Ferrans V.J., Ardalan B., Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats, Toxicol Appl Pharmacol, 78, pp. 202-214, (1985)

[6]

Ewer M., Gianni L., Pane F., Sandri M.T., Steiner R.K., Wojnowski L., Et al., Report on the international colloquium on cardio-oncology, Ecancermedicalscience, 8, (2014)

[7]

Lotrionte M., Biondi-Zoccai G., Abbate A., Lanzetta G., D'Ascenzo F., Malavasi V., Et al., Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity, Am J Cardiol, 112, pp. 1980-1984, (2013)

[8]

Cardinale D., Colombo A., Bacchiani G., Tedeschi I., Meroni C.A., Veglia F., Et al., Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy, Circulation, 131, pp. 1981-1988, (2015)

[9]

Armstrong G.T., Joshi V.M., Ness K.K., Marwick T.H., Zhang N., Srivastava D., Et al., Comprehensive Echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime cohort study, J Am Coll Cardiol, 65, pp. 2511-2522, (2015)

[10]

Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., Sanders S.P., Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood, N Engl J Med, 324, pp. 808-815, (1991)

← 1 2 3 4 5 6 7 8 9 10 →